Tag archive for ‘TEVA PHARMACEUTICAL INDUSTRIES LIMITED’
Jewish Business News On Sunday, October 11th, 2015

Shareholder Novartis to invest additional $15 million in Israeli co Gamida Cell

  Multinational pharmaceutical giant Novartis International AG (NYSE: NVS) has announced that it is investing up to an additional $15 million in Israeli Gamida Cell . Gamida Cell develops cellular and immune More...

Jewish Business News On Thursday, October 1st, 2015

Teva acquires Mexican Rimsa pharmaceutical for $2.3 billion

  Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) is acquiring Rimsa,  an independent pharmaceutical company in Mexico with a portfolio of products and patents in Latin America and Europe More...

Teva Pharmaceuticals and IBM Partner to Develop Global Health Solutions

IBM has selected Israeli Teva Pharmaceutical Industries Ltd. as its first foundational life sciences partner for the Watson Health Cloud. Financial terms of the partnership were not disclosed. Earlier this More...

Teva buys 51% stake in Genomic-Analysis Company Immuneering for $60 million

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) has announced the acquisition of 51% of Immuneering Corporation, a privately-held genomic-analysis company based in Cambrige, Massachusetts. More...

Shiri Habib-Valdhorn On Monday, July 27th, 2015

Three Way Takeover Battle – The End: Teva losing $300 million on Mylan stake

  Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has officially announced that it is withdrawing its bid to buy generic pharmaceuticals rival Mylan N.V. after agreeing to buy Allergan Generics More...

Niva Goldberg On Sunday, July 26th, 2015

Three Way Takeover Battle: Teva set to buy Allergan’s generics unit – WSJ

Teva likely mean the end of Teva’s pursuit of another Teva Pharmaceutical Industries Ltd. likely mean the end of pursuit of Mylan acquisition. The Israeli world’s biggest generic pharmaceutical maker More...

Niva Goldberg On Thursday, July 23rd, 2015

Three ways takeover battle: Mylan invokes “poison pill” to block Teva hostile takeover

  Dutch Stichting Foundation notified Mylan that it has exercised its call option to acquire 488, 388, 431 Mylan preferred shares pursuant to the Call Option Agreement, dated April 3, 2015, between More...

Teva launches generic migraine treatment

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) has launched generic treatment is for migraine, Axert (almotriptan malate) tablets in 6.25 mg and 12.5 mg dosages, in the US. Teva is the first More...

Niva Goldberg On Tuesday, July 7th, 2015

Three Way Takeover Battle: Teva plans raising Mylan bid to $43 billion – report

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA), the Israeli drugmaker, is preparing to improved proposal for US rival Mylan to as much as $43 billion, $86 to $88 a share, as soon as this More...

Shiri Habib-Valdhorn On Wednesday, July 1st, 2015

Teva CEO: The industry is undergoing a shakeup

“Size is important in the industry, but it isn’t everything. It’s important to be better. You have to make acquisitions that will suit the company’s strategic direction and contribute More...

Wordpress site Developed by Fixing WordPress Problems